Biomarin Pharmaceutical INC BIOMA.../ US09061G1013 /
| 2024-01-23 12:00:00 AM | Chg. - | Volume | Bid6:00:07 AM | Ask6:00:07 AM | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 94.04USD | - | 514 Turnover: - |
-Bid Size: - | -Ask Size: - | 14.52 bill.USD | - | 85.90 |
GlobeNewswire
05-22
Shuttle Pharma to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024
GlobeNewswire
05-22
Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $57...
GlobeNewswire
05-22
Cytokinetics and Royalty Pharma Announce Expanded Strategic Funding Collaboration Totaling Up to $57...
GlobeNewswire
05-22
DP World Receives First Freighter Aircraft at New Air Cargo Logistics Hub in Dominican Republic
GlobeNewswire
05-22
A Bold Step Forward: Trial Equity and Miller Tanner Associates Partner to Champion Diversity in Clin...
GlobeNewswire
05-22
Optimi Health, ATMA Sign Letter of Intent To Advance Phase II Clinical Trial Group and Individual Ad...
GlobeNewswire
05-22
AGC Biologics and BioConnection Partner to Offer new End-to-End Biopharmaceutical Drug Substance and...
GlobeNewswire
05-22
Crinetics Pharmaceuticals Announces Early Release of ENDO 2024 Late-Breaking Abstracts
GlobeNewswire
05-22
Adlai Nortye Announces First Patient Dosed in Randomized Phase II Clinical Trial of Palupiprant (AN0...
GlobeNewswire
05-22
Tonix Pharmaceuticals to Deliver an Oral Presentation and Present Two Posters at the American Societ...
GlobeNewswire
05-22
Oruka Therapeutics Expands Leadership Team with Appointment of Industry Veterans Drs. Joseph Senn an...
GlobeNewswire
05-22
Mesa Laboratories, Inc. Revises Earnings Announcement date for Unaudited Fourth Quarter and Full Fis...
GlobeNewswire
05-16
Oragenics, Inc. Prepares Intranasal Pharmaceutical, ONP-002, for Phase II Concussion Trial
